Clinical & Medical Strategy
Intended purpose, target population, clinical claims, value proposition, clinical development planning, unmet-need analysis, evidence gap assessment and medical affairs strategy.
Clinovexa supports MedTech and digital health companies across the full product lifecycle, combining medical affairs, clinical research, biostatistics, regulatory evidence, SaMD strategy, medical writing, education and international healthcare development.
Clinovexa helps companies connect product development, clinical evidence, regulatory strategy, post-market learning and physician adoption into one coherent development pathway.
Intended purpose, target population, clinical claims, value proposition, clinical development planning, unmet-need analysis, evidence gap assessment and medical affairs strategy.
Research questions, study protocols, endpoint strategy, comparator selection, feasibility, observational studies, clinical investigations and multicentre research planning.
Statistical analysis plans, sample-size strategy, estimands, subgroup and interaction analysis, modelling, interpretation and evidence synthesis.
Clinical Evaluation Reports, State of the Art reviews, literature evaluation, evidence synthesis, benefit-risk narratives, scientific reports and regulatory medical writing.
Post-market surveillance strategy, PMCF planning, PMCF evaluation, safety and performance trending, evidence updates and post-market clinical learning.
Clinical strategy for software as a medical device, algorithm validation, performance evaluation, clinical evidence planning, human factors and digital health research.
Clinical evidence strategy for EU MDR, evidence-gap remediation, notified-body response support, risk-benefit alignment and integration of clinical, risk and post-market evidence.
Advanced physician education, procedural training, clinical implementation, simulation, KOL engagement, advisory boards and technology adoption programmes.
Medical leadership, evidence roadmaps, launch preparation, scientific communication, market development, health-economic thinking and clinical partnership strategy.
Clinovexa works at the interface of medicine, technology and research, supporting the development, validation and commercialisation of advanced healthcare solutions.
Technology is valuable only when it solves a meaningful clinical problem, generates reliable evidence and can be implemented safely within real healthcare workflows.
Clinovexa develops and supports complex healthcare initiatives that combine clinical expertise, technology, education, implementation and system-level design.
Integrated programmes for advanced prehospital care, trauma systems, disaster preparedness, civil protection, mass-casualty response, hospital resilience, simulation and emergency technology.
Strategic market development, clinical partnerships, technology integration, healthcare consulting, government engagement and cross-border collaboration between healthcare systems and industry.
Clinical problem, intended purpose, population and claims.
Evidence plan, protocol, endpoints, statistics and validation.
Clinical, regulatory and medical documentation.
Safety, performance, clinical benefit and value.
Education, implementation, adoption and post-market learning.
Clinovexa is a Swedish health technology and clinical development company focused on MedTech, digital health, evidence generation, medical affairs and international healthcare innovation.
Clinovexa supports MedTech and digital health companies across the full product lifecycle, from intended purpose and clinical strategy through research design, biostatistics, CER, SOTA, PMS, PMCF, SaMD evidence, regulatory development, medical writing, education and post-market learning.
The company also develops and supports innovation projects, advanced healthcare technology programmes, and international healthcare-system initiatives in areas including cardiovascular care, trauma, emergency medicine and disaster preparedness.
Dr Mohamed Atwa is the Founder and Owner of Clinovexa.
He is a physician and MedTech clinical leader with extensive experience in cardiac surgery, intensive and peri-operative care, advanced cardiovascular technologies, clinical research, medical affairs and medical-device development.
His work spans the MedTech lifecycle, including clinical strategy, intended use and claims, research protocols, biostatistics and statistical analysis plans, clinical evaluation, State of the Art, PMS, PMCF, SaMD evidence, regulatory clinical development, physician education and international technology implementation.
He also holds postgraduate training in clinical-trial statistics, healthcare quality and healthcare management, with a particular interest in translating clinical problems into evidence-based and commercially scalable healthcare solutions.
For consulting, research collaboration, technology development or international healthcare partnerships, contact Clinovexa.